Drug Trial Radar · NCT06943820
AK129 Combination Therapy for Advanced Solid Tumors
Last checked: Nov 19, 2026Latest source record: Jun 3, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
230
Planned (sponsor's estimate)
Start
May 21, 2025
Primary completion
Dec 2026
Study completion May 2028
Sponsor
- Lead sponsor
- AkesoIndustry
- Sponsor type
- Industry
- First posted
- Apr 24, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an open, multicenter phase Ib/II clinical study. The goal of this study is to confirm the Phase II recommended dose (RP2D) of AK129 combinations for advanced solid tumors and evaluate the safety and efficacy of AK129 combinations for non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), colorectal adenocarcinoma (CRC), and other advanced solid tumors.
Conditions
- Non-small Cell Lung Cancer Stage IIIB/IV
- Head and Neck Squamous Cell Carcinoma (HNSCC)
- Colorectal Adenocarcinoma
- Advanced Solid Tumors
Interventions
AK129(dose 1)Drug
IV infusion
PemetrexedDrug
IV infusion;500mg/m2
PaclitaxelDrug
IV infusion;175mg/m2
CarboplatinDrug
IV infusion;AUC 5
AK129(dose 2)Drug
IV infusion
DocetaxelDrug
IV infusion;75mg/m2
Cis-platinumDrug
IV infusion;100 mg/m2
5-FU (5-fluorouracil)Drug
IV infusion;1000 mg/m2
CetuximabDrug
IV infusion;400mg/m2/ 250mg/m2
PaclitaxelDrug
IV infusion;80mg/m2
DocetaxelDrug
IV infusion;35mg/m2
ChemotherapyDrug
IV infusion
AK129(RP2D)Drug
IV infusion
PenpulimabDrug
IV infusion;200mg
Primary outcomes
What the sponsor says the trial is designed to measure.
- Frequency and severity of adverse events (AEs) ,Clinically significant abnormal laboratory resultsTime frame: Up to approximately 2 years
- Overall Response Rate (ORR)Time frame: Up to approximately 2 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Liaoning Cancer Hospital
Shenyang, Liaoning, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.